8-K current report · filed Aug 6, 2026

Generate Biomedicines Inc (GENB) 8-K Current Report: August 6, 2026

Item 2.02Item EX-99.1GENB overview

Short answer

Generate Biomedicines Inc (GENB) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release announces Generate Biomedicines’ financial results for the quarter ended June 30, 2026.

Generate Biomedicines Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Press release announces Generate Biomedicines’ financial results for the quarter ended June 30, 2026
  • Exhibit 99.1 contains the detailed financial results and management commentary

Item EX-99.1 · Exhibit EX-99.1

  • Q2 2026 revenue $6.3M, down from $10.1M, signaling lower collaboration activity from Amgen and Novartis
  • Net loss $67.3M, versus $56.7M, as R&D increased to $64.3M for Phase 3 asthma investment
  • Cash, equivalents and marketable securities $457.4M, down from $516.6M at March 31, supporting operations into H1 2028
  • GB-0895 Phase 3 asthma recruitment underway across six regions, with approvals in 33 of 42 planned countries
  • GB-4362 first Phase 1 cohort fully enrolled and initially dosed, while Novartis advanced a platform-designed biologic into preclinical development

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Generate Biomedicines Inc 8-K filings

Get the next GENB 8-K as it lands

Follow GENB for push alerts, or ask the research agent what this filing means.